FSGS is short for Focal Segmental Glomerular Sclerosis. It is not an isolated disease, but presents a kind of kidney damage. In most cases, the prognosis of FSGS is bad. Without proper treatments in time, many of the patients will end with End Stage Renal Failure.
FSGS is a severer form of Nephrotic Syndrome. Therefore, in the conventional
therapies, when their disease is mild, the patients just receive relative
treatments to reduce the amount of protein escaping from the kidneys. However,
those treatments can not repair the sclerotic glomerulus so the patients can not
improve their renal function at all. As a result, it will develop into End Stage
Renal Failure and the patients have to depend on dialysis or kidney transplant
to maintain their life. For the patients with FSGS, the key point of treatment
is to repair the sclerotic glomerulus.
With the development of regenerative medicine, Immunotherapy brings new hope
to all the patients with FSGS.
Immunotherapys are a group of undifferentiated original cells. Under right
conditions, they can regenerate new cells with the same characteristics of the
original cells or differentiate into new cells with specific functions and even
tissues or organs.
In the treatment of FSGS, Immunotherapy can differentiate into new cells to
replace the damaged renal intrinsic cells to play their roles. In addition,
Immunotherapy can provide some nutrition factors for repairing the damaged cells
so as to accelerate the repairing process. As a result, the patients are able to
improve their kidney function greatly.
In many years’ clinical practices, Immunotherapy has showed its tremendous
therapeutic advantages in treating FSGS.